Bao-Hui Han (Baohui Han)

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Shengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal for immunotherapy of cancer 12 (2) (2024)
Shengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal for immunotherapy of cancer 12 (2) (2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Bao-Hui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Bao-Hui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Shengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal for immunotherapy of cancer 12 (2) (2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Bao-Hui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Bao-Hui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Bao-Hui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for immunotherapy of cancer 12 (4) (2024)

Bao-Hui Han.css-eqlu8i{font-size:small;padding-left:4px;} (Baohui Han)

Publication Activity (10 Years)

Top Topics

Top Venues

Bao-Hui Han (Baohui Han)